This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Minimal change disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Minimal change nephropathy is responsible for 90% of the cases of nephrotic syndrome in children less than 5 years of age. It also occurs in adults - approximately 20%.

The name is derived from the fact that the only detectable abnormality histologically is fusion and deformity of the foot processes under the electron microscope. Both light microscopy and immunofluorescence are unremarkable.

The condition is most frequent in children aged between two and four years. It has been suggested that MCD is more common in atopic patients, especially those possessing HLA-DR7. However, a direct link between allergic sensitisation and the onset of MCD is yet to be established.

MCD is steroid-responsive and, in general, does not lead to chronic renal failure.

With respect to interventions for MCD in adults a systematic review concluded (1):

  • calcineurin inhibitors and enteric-coated mycophenolate sodium may be effective in achieving remission in adults with nephrotic syndrome due to MCD with some reduction in the side effects of high dose prednisolone therapy

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.